MaxCyte to Participate in Upcoming Investor Conferences
12 nov. 2021 08h00 HE
|
MaxCyte, Inc
GAITHERSBURG, Md., Nov. 12, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies...
MaxCyte Reports Third Quarter Financial Results
10 nov. 2021 16h00 HE
|
MaxCyte, Inc
GAITHERSBURG, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies...
MaxCyte Board Member Richard Douglas, PhD, Appointed Chairman of the Board
03 nov. 2021 09h00 HE
|
MaxCyte, Inc
GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN) is a leading commercial cell-engineering company focused on providing enabling platform...
Result of AGM
29 oct. 2021 12h40 HE
|
MaxCyte, Inc
GAITHERSBURG, Md., Oct. 29, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies...
MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs
28 oct. 2021 10h00 HE
|
MaxCyte, Inc
SOUTH SAN FRANCISCO and GAITHERSBURG, Md., Oct. 28, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo cell...
MaxCyte to Report Third Quarter 2021 Financial Results on November 10, 2021
25 oct. 2021 16h30 HE
|
MaxCyte, Inc
GAITHERSBURG, Md., Oct. 25, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies...
MaxCyte Set to Join Russell 2000® Index
17 sept. 2021 08h35 HE
|
MaxCyte, Inc
GAITHERSBURG, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform...
MaxCyte Reports Second Quarter and Half-Year 2021 Financial Results Provides Preliminary 2021 Revenue Projections
13 sept. 2021 16h05 HE
|
MaxCyte, Inc
GAITHERSBURG, Md., Sept. 13, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell engineering company focused on providing enabling platform...
MaxCyte to Report Second Quarter 2021 Financial Results on September 13, 2021
02 sept. 2021 08h05 HE
|
MaxCyte, Inc
GAITHERSBURG, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell engineering, today...